Enlivex Therapeutics Ltd.
ENLV
$1.05
-$0.05-4.55%
NASDAQ
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Net Income | -5.18M | -2.60M | -3.10M | -4.14M | -9.10M |
| Total Depreciation and Amortization | 36.00K | 161.00K | 160.00K | 188.00K | 200.00K |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 385.00K | 1.32M | 569.00K | 404.00K | 2.60M |
| Change in Net Operating Assets | 671.00K | -1.50M | 570.00K | -962.00K | 1.02M |
| Cash from Operations | -4.08M | -2.62M | -1.80M | -4.51M | -5.28M |
| Capital Expenditure | -35.00K | -9.00K | -16.00K | -43.00K | -7.00K |
| Sale of Property, Plant, and Equipment | 296.00K | 1.77M | 1.00K | 224.00K | 51.00K |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 3.10M | -366.00K | -779.00K | 4.92M | 4.09M |
| Cash from Investing | 3.36M | 1.40M | -794.00K | 5.10M | 4.14M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 1.91M | 250.00K | 4.40M | 540.00K | 153.00K |
| Repurchase of Common Stock | -- | -- | -- | -- | -- |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -646.00K | -- | 16.00K | -16.00K | -153.00K |
| Cash from Financing | 1.26M | 250.00K | 4.42M | 524.00K | 0.00 |
| Foreign Exchange rate Adjustments | -- | -- | -- | -- | -- |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 535.00K | -970.00K | 1.83M | 1.11M | -1.14M |